Skip to main content
SpringerLink
Log in

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-Pr1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-Pr1 tumors. Three agent were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5:3–20, 1987

    Google Scholar 

  2. Polin L, Jones J, LoRusso P, Baker L, Valeriote F, Corbett, TH: Evaluation of Chemotherapeutic Agents in the SCID Mouse. AACR 36:303, 1995

    Google Scholar 

  3. Polin L, Jones J, LoRusso Baker L, Valeriote F, Corbett, TH: The SCID mouse: A better model for human tumor xenografts. AACR 36:303, 1995

    Google Scholar 

  4. Corbett T, Valeriote F, LoRusso P, et al.: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacogn, Supp 33:102–122, 1995

    Google Scholar 

  5. Kaighn ME, Lechner JF, Babcock MS, et al.: The Pasadena Cell Lines. In: Models for Prostate Cancer, Alan R Liss (ed). Inc 150 5th Ave, NY, pp 85–109, 1980

  6. Ilzumi T, Yazaki T, Kanoh S, et al.: Establishment of a New Prostatic Carcinoma Cell Line (TSU-PR1). J Urol 137:1304–1306, 1987

    Google Scholar 

  7. Corbett TH, Roberts BJ, Trader MW, Laster WR Jr, Griswold DP Jr, Schabel FM Jr: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5):1187–1200, 1982

    Google Scholar 

  8. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42:1707–1715, 1982

    Google Scholar 

  9. Corbett TH, Valeriote FA: Rodent Models in Experimental Chemotherapy, The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, RF Kallman (ed) Pergamon Press, Chapt 50, pp 233–247, 1987

  10. Corbett TH, Bissery M-C, LoRusso P-M, Polin L: 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 7:37–49, 1989

    Google Scholar 

  11. Corbett TH, Valeriote FA, Polin L, et al.: Discovery of solidtumor active agents using a soft-agar-colony-formation disk-diffusion-assay. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. FA Valeriote, TH Corbett and LH Baker (eds) Kluwer Academic Publishers, pp. 33–87, Boston/Dordrecht, London, 1992

    Google Scholar 

  12. Carter CA, Dykes DJ: Characterization of tumor growth and drug sensitivity for human prostate tumors implanted orthotopically. Proc Am Assoc Cancer Res 35:280, 1994

    Google Scholar 

  13. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of Cryptophycin-8. J Exp Ther Oncol 2:1996

  14. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ: Taxol in advanced, hormone-refractory carcinoma of the prostate cancer 72:2457–2460, 1993

    Google Scholar 

  15. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR Jr, Simpson-Herren L, Griswold DP Jr: Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel, Karger, Vol 42, pp 1–22, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI, 48201

    Lisa Polin, Frederick Valeriote, Kathryn White, Chiab Panchapor, Susan Pugh, Juiwanna Knight, Patricia LoRusso, Maha Hussain & Thomas H. Corbett

  2. Nanosystems LLC, 1250 S. Collegeville Rd., Collegeville, PA

    Elaine Liversidge & Nancy Peltier

  3. Department of Chemistry, University of Hawaii, Honolulu, HI

    Trimurtulu Golakoti, Gregory Patterson & Richard Moore

Authors
  1. Lisa Polin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Valeriote
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathryn White
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiab Panchapor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Pugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juiwanna Knight
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patricia LoRusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maha Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elaine Liversidge
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nancy Peltier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Trimurtulu Golakoti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gregory Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Richard Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Thomas H. Corbett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polin, L., Valeriote, F., White, K. et al. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15, 99–108 (1997). https://doi.org/10.1023/A:1005856605726

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005856605726

Search

Navigation